FDA accountability for review times sought in Senate GOP concept paper.
This article was originally published in The Tan Sheet
Executive Summary
FDA ACCOUNTABILITY FOR REVIEW DEADLINES IS SOUGHT in Senate Labor & Human Resources Committee Chair Nancy Kassebaum's (R-Kan.) FDA reform concept paper. If the agency "fails to meet statutory deadlines for product review," the paper states, the appropriate FDA office director would be required "within seven days of the missed deadline" to inform the product sponsor in writing: "(1) of the reasons why additional time is necessary; (2) each remaining issue relating to the application; and (3) the projected date for completion."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning